Abstract
dc:description.abstract<p>This project has explored the effects of CD40 ligation of a variety of CD40 expressing tumours including transformed human B cell lines (RL and Daudi), human epithelial cell lines (MG79 [ovarian] and Cask [cervical]) and primary human B cell non-Hodgkin’s lymphomas obtained, with consent, from patients undergoing excision lymph mode biopsy or splenectomy.</p> <p>The ligation of CD40, on transformed human B cell lines, using Chinese hamster ovary cells transfected to express human CD40L and human soluble CD40L has shown significant cellular growth inhibition (p<0.001). Ligation of CD40 on human epithelial cell lines using human soluble CD40L has also resulted in significant growth inhibition.</p> <p>In primary B cell human non-Hodgkin’s lymphomas ligation of CD40 with both CD40L expressing CHO cells and human soluble CD40L in the presence of human IL4 has caused significant cellular proliferation (p<0.001) and induced upregulation of cell surface and costimulatory molecules including CD80, CD86, CD58, CD54.</p> <p>Anti-tumour activity has been identified in a xenograft model of a transformed human B cell line (Daudi) treated with both a mouse anti-human CD40 antibody and a chimeric human anti-CD40 antibody.</p> <p>I have performed important preclinical toxicology studies testing mouse anti-CD40 (3/23) by injecting the antibody intraperitoneally or intravenously in to BALB/c mice. The mice have been culled following treatment and a reversible dose dependent transaminitis associated with microscopic evidence of a reversible lympho-granulomatous hepatitis, that at the highest dose levels is acutely necrotising, has been identified. These anti-CD40 antibody toxicology studies are essential before a protocol for a phase I trial of human anti-CD40 antibody against CD40 expressing human tumours is developed.</p> <p>I have developed a new chimeric human anti-CD40 antibody containing human constant regions and mouse variable regions. This antibody is currently undergoing large scale production for a proposed trial to treat patients with CD40 expressing tumours (excluding low-grade non-Hodgkin’s lymphoma) who have failed conventional therapies.</p>
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D.
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of Southampton
- Year dc:date.issued
- 2002
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Harvey, Melanie Louise
Rights
- Language dc:language
- English, eng